A multicenter, placebo-controlled, double-blind, two-phase crossover study of Nasalfent (fentanyl citrate nasal spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid therapy.

Trial Profile

A multicenter, placebo-controlled, double-blind, two-phase crossover study of Nasalfent (fentanyl citrate nasal spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2012

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2010 Results have been published in Pain, according to an Archimedes Pharma media release.
    • 25 Jun 2010 The Committee for Human Medicinal Products (CHMP) has recommended the approval of fentanyl based on three phase III trials including this trial.
    • 05 Oct 2009 Additional lead trial investigator (Gupta R) added as reported by New Jersey Cancer Trial Connect record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top